Stuart Friedrich

Robust Central Reduction of Amyloid-β in Humans with an Orally Available, Non-Peptidic β-Secretase Inhibitor

Patrick C. May, Robert A. Dean, Stephen L. Lowe et al. · Journal of Neuroscience · 2011 · 369 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +16

A γ‐secretase inhibitor decreases amyloid‐β production in the central nervous system

Randall J. Bateman, Eric Siemers, Kwasi G. Mawuenyega et al. · Annals of Neurology · 2009 · 323 citations · Full text

Life Sciences, Neuroscience, Pharmacology +12

Safety and biomarker effects of solanezumab in patients with Alzheimer's disease

Martin R. Farlow, Steven E. Arnold, Christopher H. van Dyck et al. · Alzheimer s & Dementia · 2012 · 275 citations

Medicine, Neurology, Pharmacology +17

Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Ulcerative Colitis

William J. Sandborn, Marc Ferrante, Bal Raj Bhandari et al. · Gastroenterology · 2019 · 221 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Safety and Changes in Plasma and Cerebrospinal Fluid Amyloid β After a Single Administration of an Amyloid β Monoclonal Antibody in Subjects With Alzheimer Disease

Eric Siemers, Stuart Friedrich, Robert A. Dean et al. · Clinical Neuropharmacology · 2010 · 189 citations

Medicine, Neurology, Pharmacology +17